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position grafts, a 6 Both models have produced lesions that resemble 
human transplantation arteriosclerosis. 
The recent availability of many mutant mice that have specific 
targeted gene disruptions generated by homologous recombina- 
tion (gene "knockout") illustrates the particular value of mice. For 
technical reasons, homologous recombination has generally used 
embryonic stem (ES) cells from the 129 strain, and the mutations 
must be subsequently bred into more conventional strains for use 
in immunologic experiments. The availability of ES cells from other 
strains may obviate this inconvenience. Many such animals are now 
widely available in the research community, a number of which bear 
particular interest for analysis of the immune mechanisms of 
transplantation arteriosclerosis. Efforts are currently underway in 
several laboratories toexploit his approach to learn more about he 
pathogenesis of graft vascular disease. 
Peter Libby, MD 
Brigham and Women's Hospital 
Boston, Mass. 
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MURINE MODELS OF 
FIBRINOLYTIC D ISORDERS 
Object ives  
The plasminogen/plasmin system, via its triggers, tissue-type 
plasminogen activator (t-PA) and urokinase-type plasminogen 
activator (u-PA) and its inhibitor, plasminogen activator inhibitor- 1
(PAI-1), has been presumed to be implicated in arterial restenosis 
after vascular econstruction i patients with atherothrombotic 
disease. This study performed in mice with targeted gene inactiva- 
tion of t-PA, u-PA, PAI-1, the urokinase receptor (u-PAR) and 
plasminogen (Pig) reveals that vascular injury-induced neointima 
formation is reduced in mice that lack uPA-mediated plasmin 
proteolysis unaltered int-PA-deficient or u-PAR-deficient mice and 
accelerated in PAI-1 deficient mice, most likely by means of a 
mechanism of reduced cell migration combined with unaffected 
cell proliferation. These findings were extended by adenovirus- 
mediated gene transfer of PAI-I in PAI-1 deficient mice, which 
inhibits neointima formation to the same degree as observed in 
u-PA deficient mice. Thus inhibition ofu-PA activity in the injured 
vessel wall might prevent or delay arterial neointima formation. 
Surprisingly, u-PA does not require binding to its cellular eceptor 
herefore, questioning the in vivo role of u-PAR. 
In t roduct ion  
The plasminogen system comprises an inactive proenzyme, 
plasminogen (Plg), that is converted to the proteolytic enzyme 
plasmin by two physiologic plasminogen activators, tissue-type 
plasminogen activator (t-PA) and uroldnase-type plasminogen 
activator (u-PA).l Inhibition of the fibrinolytic system may occur at 
the level ofplasmin, mainly by a 2 antiplasmin, orat the level of the 
plasminogen activators by specific plasminogen activator inhibitors 
(PAIs), of which PAI~I appears to be the principal inhibitor. 2 t-PA 
is believed to be ptimarily responsible for removal of fibrin from the 
vascular tree through its specific affinity for fibrin) u~PA binds to a 
cellular receptor (u-PAR) and might participate in pericellular 
proteolysis by means of degradation of matrix components or via 
activation of latent proteinases or growth factors. 3 Cell-specific 
clearance ofplasminogen activators by LDL receptor-related pro- 
tein (LRP) or gp330 might constitute a mechanism to modulate 
pericelhilar plasmin proteolysis. 
Vascular econstructions, including coronary angioplasty, en- 
darterectomy, bypass urgery, vascular stents, and heart ransplan- 
tation, have become widely used treatments for patients with 
atherothrombotic d sease. However, chronic restenosis n 30% to 
50% of patients, necessitating costly and complicated reinterven- 
tions, remains amajor limitation of these procedures. Elastic recoil, 
adventitial remodeling, and thrombosis have been implicated in the 
process. Kestcnosis i , however, frequently characterized byexces- 
sive accumulation of smooth muscle cells and deposition of 
extracellular matrix in the intimal ayer due to an uncontrolled 
wound healing process in response to vascular trauma. Recently, 
evidence has been provided for a significant role of the plasminogen 
system in vascular wound healing. In an uninjured vessel, expres- 
sion oft-PA by endothelial cells and, to a variable xtent, of PAI-1 
by medial smooth muscle cells suggests a role in maintaining 
vascular patency and hemostasis, respectively. 4-6 After transient 
reduction oft-PA as a result of endothelial cell damage, u-PA and 
t-PA activity in the vessel wall are significantly increased, coincident 
with the time of smooth muscle cell proliferation and migration, 
respectively. 7-9 This increase in plasmin proteolysis appears to be 
counterbalanced by enhanced expression of PAI-1 in injured 
smooth muscle and endothelial cells or by its release from accumu- 
lating platelets. 7,1°,n Expression of fibrinolytic system components 
is also induced by wounding or treatment of cultured endothelial 
cells, smooth muscle cells, or macrophages with growth factors and 
cytokines that are released after injury, 12a3 further supporting a
possible role of this proteinase system in vivo. Local increases of 
plasmin proteolysis n the injured vessel may participate in clot lysis 
( a possible mediator of neointima formation), in passivation ofthe 
injured vessel lumen, or in matrix remodeling. In addition, plas- 
minogen activators have been implicated in migration as well as 
proliferation of vascular cells in vitro and in vivo. 7-9'14 
Resu l ts  and  d iscuss ion  
Arterial neointima formation was induced in mice with inac- 
tivated genes oft-PA, u-PA, u-PAR, Pig, PAI-1 or with combined 
deficiency of t-PA and u-PA, lsq9 using either an intraluminai 
guidewire to overextend and scratch the vessel (mechanical trauma) 
or externally applied electric current o deplete a defined vessel 
fragment of viable cells (electric injury). Electric injury of carotid 
and femoral arteries from wild-type (WT) mice resulted in total 
cellular necrosis across the vessel wall with associated periadventitial 
inflammation and formation of intravascular thrombosis, as re- 
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vealed within 2 days after injury. At 21 days, healing of the arterial 
injury in WT mice was associated with formation of neointima that 
consisted predominantly of anti-alpha actin immunoreactive SMCs 
and of a minor population (5% to 10%) of anti-CD45 immunore- 
active inflammatory cells. Neointima first appeared at the borders of 
the injury (presumably due to proliferation and migration of viable 
SMCs across the internal elastical membrane) and progressed 
towards the necrotic enter (presumably due to migration of medial 
and neointimal SMCs). In contrast to the electric injury model, 
guidewire injury did not deplete the media of all viable SMCs and 
(presumably as a result of proliferation and migration of medial 
SMCs across the internal elastical membrane) induced uniform 
neointima formation over the entire length of the injury. 
Comparative morphometric analysis revealed that deficiency of 
t-PA or u-EAR does not affect the degree or rate of neointima 
formation, but that deficiency ofPAI- 1 significantiy accelerates and 
that deficiency ofu-PA, Plg, or the combined eficiency oft-PA and 
u-PA greatly reduces and delays neointima formation and neointi- 
mal accumulation fsmooth muscle cells.2° Furthermore, progres- 
sion ofneointima from the uninjured borders into the center of the 
electrically injured region (which is depleted of viable smooth 
muscle cells by the electrical injury) occurred at an increased rate in 
PAl-l-deficient compared with u-PA-deficient arteries. These 
results were extended by adenovirus-mediated PAl-1 gene transfer 
in PAl-1 deficient mice after vascular injury, which induced plasma 
PAl-1 levels 100- to 1000-fold above WT and inhibited neointima 
formation to the same extent as observed in u-PA-deficient mice. 
The same genotype-related differences as observed in the electrical 
injury model namely, reduced neointima formation in u-PA-de- 
ficient mice and increased neointima formation in PAl- 1 deficient 
mice--were observed after mechanical injury. Because cellular 
proliferation was similar in all genotypes, u-PA appears to promote 
neointima formation by facilitating cellular migration rather than 
proliferation. Our data suggest that n-PA rather than t-PA contrib- 
utes to vascular wound healing and neointima formation in mice. 
Further study is required to elucidate whether other mechanisms, 
including apoptosis or matrix remodeling, are affected by these 
genetic manipulations, assuggested by our previous observations 
of impaired degradation of 3H-proline-labeled subendothelial 
matrix by u-PA-deficient but not by t-PA-deficient macrophages) 7 
It is possible that u-PA-facilitated cellular migration isinvolved not 
only in neointima formation, as demonstrated in the present study, 
but also in other processes of vascular emodeling, such as after 
transplantation, during hypertension, atherosclerosis, or aneurysm 
formation. Appropriate local control ofu-PA activity after vascular 
trauma might constitute a new therapeutic approach to arterial 
neointima formation after coronary angioplasty. 
Peter Carmelie~, MD, PhD 
Katholieke Uni~ersiteit Leuven 
Leu~en, Belgium 
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ARTERIAL RESPONSE TO INJURY IN 
THE MOUSE 
We have used animal models to determine what factors may be 
important in the growth of arterial esions. This approach as 
allowed us to identify the role of growth factors and how they relate 
